Investigation Management

What investigation management is

Investigation management is how a firm examines quality events — deviations, OOS, complaints, audit findings, supplier issues, failed effectiveness checks — to determine cause, impact, and required corrective action. It's the analytical work that turns a flagged issue into a credible decision: assignment, evidence collection, root cause analysis, impact assessment, conclusion, CAPA linkage.

Rigorous investigations produce CAPAs that work and recurrence rates that fall. Weak investigations produce repeat findings the next inspection cycle, even when the paperwork looks complete. The investigation is where the quality system actually thinks; tick-box investigations skip the thinking and accept the first plausible explanation.

21 CFR §211.192 requires investigation of any unexplained discrepancy. 21 CFR §820.100 requires investigation as part of CAPA. EU GMP Chapter 1 §1.4(xiv) requires deviations to be investigated and documented. ICH Q10 §3.2.2 places investigation inside the CAPA system as the foundation for effective action. The discipline is universal across modern quality frameworks.

Why investigation quality is the strongest signal of QMS maturity

Inspectors read investigations the way doctors read medical histories. The investigation tells them whether the firm actually understood what happened, what mattered, and what was at stake. A thoughtful investigation with documented evidence, cross-functional input, and substantive root cause analysis gives confidence. A superficial one — single perspective, evidence-thin, blaming human error without system context — signals that the broader quality system probably has similar gaps.

The 2023 ICH Q9(R1) revision sharpened expectations on investigation specifically. R1 emphasises deliberate hazard identification (which depends on cross-functional input), subjectivity awareness (which depends on multi-perspective evidence review), and bias mitigation (which addresses the 'human error' reflex that single-perspective investigations produce). Programs running on pre-2023 investigation discipline are increasingly cited for these specific gaps.

Recurrence is also a strong inspection signal. When inspectors find repeat events with the same or similar root cause, they trace back to the original investigation. Typically they find that the original investigation accepted a shallow root cause or didn't address systemic factors. The recurrence isn't the finding. The investigation that allowed it is.

Inspector perspective: a useful sample is to read three investigations from the past year and ask three questions of each one. Were multiple perspectives present in the analysis? Did the team consider system factors, not just individual factors? Was the conclusion supported by documented evidence, or was it the first plausible explanation? An investigation that reads like one person's view of what happened triggers a wider sample. The pattern across the sample tells inspectors about the program's maturity, not just the specific event.

Where investigation obligations come from

Investigation is required across most GxP frameworks:

• 21 CFR §211.192: any unexplained discrepancy or batch failure shall be thoroughly investigated. The principal U.S. drug investigation requirement.
• 21 CFR §211.180(e): quality unit responsibility for evaluation; investigations are a primary record type.
• 21 CFR §820.100(a)(2): investigate the cause of nonconformities relating to product, processes, and the quality system.
• 21 CFR §820.198(c): investigation of complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications.
• 21 CFR §820.90: investigation of nonconformance per established procedures.
• EU GMP Chapter 1 §1.4(xiv): deviations are investigated and documented.
• EU GMP Chapter 8: complaints and product defects management, investigation included.
• EU GMP Chapter 5: investigation of production deviations including supplier-related issues.
• ICH Q10 §3.2.2 (CAPA): investigation as the foundation for effective corrective action.
• ICH Q9(R1) (effective 2023): risk-based investigation depth; bias awareness; multi-perspective discipline.
• ISO 13485 §8.3: investigation of nonconforming product.
• ISO 13485 §8.5.2: corrective action, investigation of cause included.
• ISO 9001:2015 §10.2: nonconformity and corrective action, investigation included.
• FDA OOS Guidance (October 2006): investigation framework for OOS results specifically.
• FDA Data Integrity Q&A (December 2018): investigation of data integrity issues.
• MHRA GxP DI guidance (March 2018, updated September 2021): investigation discipline as part of data integrity governance.

The investigation lifecycle from trigger to closure

A defensible investigation moves through these stages:

• Trigger and assignment. An event meeting investigation criteria (deviation, OOS, complaint above threshold, audit finding above severity, failed effectiveness check, supplier issue) triggers an investigation record. It's assigned to an investigator appropriate to event type and severity.
• Initial scoping. Investigator defines scope: what the event was, immediate containment if needed, affected batches or records, the relevant time period, applicable regulatory commitments. Scope captured early prevents drift during the investigation.
• Evidence collection. Objective evidence gathered: records (batch records, test results, audit logs), system data (instrument outputs, audit trail entries, monitoring data), interviews (documented, structured, not informal hallway conversations), photos or observations of affected area or equipment, retained samples where applicable, prior similar events.
• Cross-functional review. For significant investigations, multi-disciplinary review of the evidence — quality, manufacturing, engineering, validation, supply, regulatory as applicable. Single-perspective review produces single-perspective conclusions.
• Root cause analysis. Structured RCA using methodology matched to the event (5 Whys, Fishbone, Fault Tree, FMEA). Under ICH Q9(R1), bias awareness is explicit — 'human error' as root cause is rejected unless system factors have been deliberately ruled out.
• Impact assessment. Effects on product quality, patient safety, batches in distribution, validation state, regulatory commitments, training, suppliers.
• Conclusion and decision. Documented investigation conclusion supported by the assembled evidence. Disposition decision (batch release, reject, recall, etc.) tied to the conclusion.
• CAPA linkage. Where investigation surfaces a systemic root cause, CAPA is initiated with the investigation as source. The CAPA action plan addresses the root cause the investigation identified.
• Closure. Formal closure by QA with signed conclusion, disposition, and CAPA reference. Closure within SLA; overdue investigations escalated.
• Effectiveness verification. Where CAPA followed, an effectiveness check verifies the action addressed the root cause. Recurrence after closure flags the investigation as potentially incomplete.
• Trending. Aggregate investigation data — counts by area, root cause categories, time-to-closure, recurrence patterns — feeds CAPA prioritisation and Management Review.

What strong investigation programs do

The patterns that hold up at inspection:

• Trigger criteria explicit. What event types and severities require investigation, documented per event category.
• Scope defined early. Captured at investigation initiation; reduces drift.
• Evidence discipline. Objective evidence required for conclusions; assumptions without evidence flagged.
• Cross-functional input for significant investigations. Multi-disciplinary review reducing single-perspective bias.
• Structured RCA. Methodology appropriate to event complexity; bias awareness under Q9(R1).
• Impact assessment as part of investigation. Effects on quality, safety, batches, validation, regulatory.
• Conclusion supported by evidence. Documented reasoning chain from evidence to conclusion.
• CAPA linkage for systemic root causes. Investigation to CAPA when warranted; bi-directional reference.
• SLA-driven closure. Defined timelines per investigation type; overdue escalation.
• QA-controlled closure. Independent reviewer signs off.
• Effectiveness verification. Resulting CAPAs verified effective.
• Recurrence tracking. Closed investigations monitored for related events; recurrence flags potentially incomplete prior investigation.
• Aggregate trending. Pattern analysis across investigations; feeds CAPA prioritisation and MR.
• Training on investigation principles. Investigators trained on evidence discipline, RCA methodology, Q9(R1) bias awareness.

How Complere supports investigation management

Investigation is where your quality system actually thinks, and no platform does the thinking for you. What Complere does is give your investigators one consistent place to capture the work — so when an inspector reads back through it months later, the story is coherent, the evidence is attached, and the trail from event to root cause to corrective action is intact.

When your team logs a deviation, OOS, complaint, audit finding, or supplier issue, an investigation record opens with the trigger, severity, assignment, and the scope fields that match the event type. Your investigator builds the evidence on that record: files attached, related batches and equipment and suppliers and prior similar events linked, interview notes recorded, system data referenced. Every contribution is captured with who added it and when — so the chain of evidence is visible without anyone having to reconstruct it later.

Root cause analysis runs through a configurable structure. Your team chooses the cause categories and the RCA methodology (5 Whys, Fishbone, structured cause-effect) that match your investigation SOP. For significant investigations, your team can require multiple disciplines to sign as contributors, and the platform checks each person actually has the authority for that sign-off — so the cross-functional discipline ICH Q9(R1) expects is built into the workflow, not left to memory.

The investigation conclusion drives what happens next. When your team identifies a systemic root cause, the CAPA workflow picks up with the investigation referenced as the source. Effectiveness checks on the resulting CAPA close the loop. If a related event surfaces later, your investigators can see the prior investigation and reassess whether the original closure missed something.

What stays with your team: the investigation SOP per event type, the scope and depth call, the RCA methodology selection, the cross-functional rules, the SLA windows you defend at inspection, and the training that keeps your investigators sharp under Q9(R1). Complere supports the work; the rigour is yours.

Related investigation and follow-up terms

Investigation management connects the event detection side to the corrective action side:

• Root Cause Analysis — the analytical phase inside investigation
• Deviation — deviations trigger investigations
• OOS — OOS results require structured investigation (Phase 1 / Phase 2 per FDA 2006 guidance)
• Complaint Handling — significant complaints trigger investigations
• CAPA — investigation outcomes drive CAPA
• Risk Management — Q9(R1) principles guide investigation discipline
• Internal Audit — audit findings often trigger investigations